A new clinical trial involving thymosin alpha-1, also known as thymalfasin, was listed on ClinicalTrials.gov as of October 20, 2026. The study, titled "Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment," is registered under identifier NCT07884201. It is designated a Phase 2 trial. The current status of the trial is not yet recruiting. The trial focuses on neoadjuvant treatment in triple negative breast cancer, evaluating thymalfasin in combination with chemotherapy and immunotherapy. No enrollment, outcomes, or results have been reported at this stage. Thymosin alpha-1 remains classified as an unapproved compound under research status. As the trial has not begun recruiting participants, no efficacy or safety data from this study are currently available. Further updates would be expected once the trial moves into an active recruitment phase and begins generating data. Readers interested in the broader context of this compound, including its regulatory status and general research background, can consult the compound overview for additional information.
Thymalfasin Phase 2 Trial in TNBC Registered, Not Yet Recruiting
See the full thymosin alpha-1 overview
Source: https://clinicaltrials.gov/study/NCT07884201